Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
Che-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedic...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-12-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/preparation-of-argininendashglycinendashaspartic-acid-modified-biopoly-peer-reviewed-article-IJN |
| _version_ | 1818571093256962048 |
|---|---|
| author | Chang CY Wang MC Miyagawa T Chen ZY Lin FH Chen KH Liu GS Tseng CL |
| author_facet | Chang CY Wang MC Miyagawa T Chen ZY Lin FH Chen KH Liu GS Tseng CL |
| author_sort | Chang CY |
| collection | DOAJ |
| description | Che-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, 3Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan, 4Institute of Biomedical Engineering, National Taiwan University, 5Department of Ophthalmology, Taipei Veterans General Hospital, 6Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia *These authors contributed equally to this work Abstract: Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the αvβ3 integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by 1H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin αvβ3. In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 µg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. Keywords: RGD peptide, epigallocatechin gallate (EGCG), hyaluronic acid (HA), vascular endothelial cells, antiangiogenesis, corneal neovascularization |
| first_indexed | 2024-12-14T13:51:01Z |
| format | Article |
| id | doaj.art-d182185c1bd64859ac5390338a941c6b |
| institution | Directory Open Access Journal |
| issn | 1178-2013 |
| language | English |
| last_indexed | 2024-12-14T13:51:01Z |
| publishDate | 2016-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj.art-d182185c1bd64859ac5390338a941c6b2022-12-21T22:59:05ZengDove Medical PressInternational Journal of Nanomedicine1178-20132016-12-01Volume 1227929430710Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularizationChang CYWang MCMiyagawa TChen ZYLin FHChen KHLiu GSTseng CLChe-Yi Chang,1,2,* Ming-Chen Wang,2,* Takuya Miyagawa,1 Zhi-Yu Chen,1 Feng-Huei Lin,3,4 Ko-Hua Chen,5,6 Guei-Sheung Liu,7 Ching-Li Tseng1 1Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, 2Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, 3Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan, 4Institute of Biomedical Engineering, National Taiwan University, 5Department of Ophthalmology, Taipei Veterans General Hospital, 6Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia *These authors contributed equally to this work Abstract: Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the αvβ3 integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by 1H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin αvβ3. In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 µg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. Keywords: RGD peptide, epigallocatechin gallate (EGCG), hyaluronic acid (HA), vascular endothelial cells, antiangiogenesis, corneal neovascularizationhttps://www.dovepress.com/preparation-of-argininendashglycinendashaspartic-acid-modified-biopoly-peer-reviewed-article-IJNRGD peptideepigallocatechin gallate (EGCG)hyaluronic acid (HA)vascular endothelial cellsanti-angiogenesiscorneal neovascularization |
| spellingShingle | Chang CY Wang MC Miyagawa T Chen ZY Lin FH Chen KH Liu GS Tseng CL Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization International Journal of Nanomedicine RGD peptide epigallocatechin gallate (EGCG) hyaluronic acid (HA) vascular endothelial cells anti-angiogenesis corneal neovascularization |
| title | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| title_full | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| title_fullStr | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| title_full_unstemmed | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| title_short | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| title_sort | preparation of arginine ndash glycine ndash aspartic acid modified biopolymeric nanoparticles containing epigalloccatechin 3 gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
| topic | RGD peptide epigallocatechin gallate (EGCG) hyaluronic acid (HA) vascular endothelial cells anti-angiogenesis corneal neovascularization |
| url | https://www.dovepress.com/preparation-of-argininendashglycinendashaspartic-acid-modified-biopoly-peer-reviewed-article-IJN |
| work_keys_str_mv | AT changcy preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT wangmc preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT miyagawat preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT chenzy preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT linfh preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT chenkh preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT liugs preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT tsengcl preparationofargininendashglycinendashasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization |